Registro:

Referencias:

• (2009) Alzheimer's Disease Facts and Figures.Alzheimers Dementia, 5, pp. 234-270. , Alzheimer's Association
• Wimo, A., Winblad, B., Jönsson, L., The worldwide societal costs ofdementia: Estimates for 2009 (2010) Alzheimers Dementia, 6, pp. 98-103
• Yamin, G., Ono, K., Inayathullah, M., Teplow, D.B., Amyloid β-protein assembly as a therapeutic target of Alzheimer's disease (2008) CurrPharm Des, 14, pp. 3231-3246
• Ghosh, A.K., Gemma, S., Tang, J., β-Secretase as a therapeutic targetfor Alzheimer's disease (2008) Neurotherapeutics, 5, pp. 399-408
• Silvestri, R., Boom in the development of non-peptidic -secretase(BACE-1) inhibitors for the treatment of Alzheimer's disease (2009) Med Res Rev, 29, pp. 295-338
• Sussman, J.L., Harel, M., Frolow, F., Atomic structure of acetyl-cholinesterase from Torpedo californica, a prototypic acetylcho-line-binding protein (1991) Science, 253, pp. 872-879
• Lane, R.M., Potkin, S.G., Enz, A., Targeting acetylcholinesterase and butyrylcholinesterase in dementia (2006) Int J Neuropsychopharmacol, 9, pp. 101-124
• Lane, R.M., He, Y., Emerging hypotheses regarding the influence ofbutyrylcholinesterase-K variant, APOE e4, and hyperhomocys-teinemia in neurodegenerative dementias (2009) Med Hypothes, 73, pp. 230-250
• Greig, N.H., Utsuki, T., Ingram, D.K., Selective butyrylcho-linesterase inhibition elevates brain acetylcholine, augments learn-ing and lowers Alzheimer β-amyloid peptide in rodent (2005) Proc NatlAcad Sci USA, 102, pp. 17213-17218
• Weinstock, M., Selectivity of cholinesterase inhibition: Clinicalimplications for the treatment of Alzheimer's disease (1999) CNS Drugs, 12, pp. 307-323
• Giacobini, E., Cholinesterase inhibitors: New roles and the rapeuticalternatives (2004) Pharmacol Res, 50, pp. 433-440
• Venneri, A., McGeown, W.J., Shanks, M.F., Empirical evidence ofneuroprotection by dual cholinesterase inhibition in Alzheimer'sdisease (2005) Neuropharmacol Neurotoxicol, 16, pp. 107-110
• Giacobini, E., Spiegel, R., Enz, A., Veroff, A.E., Cutler, N.R., Inhibition ofacetyl- and butyryl-cholinesterase in the cerebrospinal fluid of pa-tients with Alzheimer's disease by rivastigmine: Correlation withcognitive benefit (2002) J Neural Transm, 109, pp. 1053-1065
• Inestrosa, N.C., Alvarez, A., Pérez, C.A., Acetylcholinesteraseaccelerates assembly of amyloid-β-peptides into Alzheimer's fi-brils: Possible role of the peripheral site of the enzyme (1996) Neuron, 16, pp. 881-891
• Inestrosa, N.C., Dinamarca, M.C., Alvarez, A., Amyloid cholinesteraseinteractions. Implications for Alzheimer's disease (2008) FEBS J, 275, pp. 625-632
• Rees, T., Hammond, P.I., Soreq, H., Younkin, S., Brimijoin, S., Acetyl-cholinesterase promotes beta-amyloid plaques in cerebral cortex (2003) Neurobiol Aging, 24, pp. 777-787
• Alvarez, A., Alarcón, R., Opazo, C., Stable complexes involvingacetylcholinesterase and amyloid- peptide change the biochemicalproperties of the enzyme and increase the neurotoxicity of Alz-heimer's fibrils (1998) J Neurosci, 18, pp. 3213-3223
• Reyes, A.E., Chacón, M.A., Dinamarca, M.C., Cerpa, W., Morgan, C., Inestrosa, N.C., Acetylcholinesterase-A complexes are more toxicthan A fibrils in rat hippocampus: Effect on rat -amyloid aggre-gation, laminin expression, reactive astrocytosis, and neuronal cellloss (2004) Am J Pathol, 164, pp. 163-174
• Rees, T.M., Berson, A., Sklan, E.H., Memory deficits correlatingwith acetylcholinesterase splice shift and amyloid burden in doublytransgenic mice (2005) Curr Alzheimer Res, 2, pp. 291-300
• Hamley, I.W., Peptide fibrillization (2007) Angew Chem Int Ed, 46, pp. 8128-8147
• Espallergues, J., Galvan, L., Sabatier, F., Rana-Poussine, V., Maurice, T., Chatonnet, A., Behavioral phenotyping of heterozygous acetylcho-linesterase knockout (AChE+/) mice showed no memory enhance-ment but hyposensitivity to amnesic drugs (2010) Behav Brain Res, 206, pp. 263-273
• de Ferrari, G.V., Canales, M.A., Shin, I., Weiner, L.M., Silman, I., Ine-Strosa, N.C., A structural motif of acetylcholinesterase that promotesamyloid beta-peptide fibril formation (2001) Biochemistry, 40, pp. 10447-10457
• Diamant, S., Podoly, E., Friedler, A., Ligumsky, H., Livnah, O., Soreq, H., Butyrylcholinesterase attenuates amyloid fibril formation in vitro (2006) Proc Natl Acad Sci USA, 103, pp. 8628-8633
• Cavalli, A., Bolognesi, M.L., Capsoni, S., A small moleculetargeting the multifactorial nature of Alzheimer's disease (2007) Angew Chem Int Ed, 46, pp. 3689-3692
• Pang, Y.P., Quiram, P., Jelacic, T., Hong, F., Brimijoin, S., Highly potent,selective, low cost bis-tetrahydroaminacrine inhibitors of acetyl-cholinesterase (1996) J Biol Chem, 271, pp. 23646-22349
• Li, W., Mak, M., Jiang, H., Novel anti-Alzheimer's dimer bis(7)-cognitin: Cellular and molecular mechanisms of neuroprotectionthrough multiple targets (2009) Neurotherapeutics, 6, pp. 187-201
• http://www.noscira.com; Castro, A., Martinez, A., Peripheral and dual binding site acetylcho-linesterase inhibitors: Implications in treatment of Alzheimer's dis-ease (2001) Mini Rev Med Chem, 1, pp. 267-272
• Cavalli, A., Bolognesi, M.L., Minarini, A., Multi-target-directedligands to combat neurodegenerative diseases (2008) J Med Chem, 51, pp. 347-372
• Muñoz-Torrero, D., Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease (2008) Curr Med Chem, 15, pp. 2433-2455
• García-Palomero, E., Muñoz, P., Usan, P., Potent -amyloidmodulators (2008) Neurodegener Dis, 5, pp. 153-156
• Loudwig, S., Nicolet, Y., Masson, P., Photoreversible inhibitionof cholinesterases: Catalytic serine-labeled caged butyrylcholineste-rase (2003) ChemBioChem, 4, pp. 762-767
• Savini, L., Gaeta, A., Fattorusso, C., Specific targeting of acetyl-cholinesterase and butyrylcholinesterase recognition sites. Rationaldesign of novel, selective, and highly potent cholinesterase inhibi-tors (2003) J Med Chem, 46, pp. 1-4
• Campiani, G., Fattorusso, C., Butini, S., Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors (2005) J Med Chem, 48, pp. 1919-1929
• Masson, P., Froment, M.T., Fort, S., Butyrylcholinesterase-catalyzed hydrolysis of N-methylindoxyl acetate: Analysis of volume changes upon reaction and hysteretic behavior (2002) Biochim Bio-phys Acta, 1597, pp. 229-243
• Lin, G., Chen, G.H., Lu, C.P., Yeh, S.C., QSARs for peripheral anionicsite of butyrylcholinesterase with inhibitions by 4-acyloxy-biphenyl-4'-N-butylcarbamates (2005) QSAR Comb Sci, 24, pp. 943-952
• Camps, P., Formosa, X., Muñoz-Torrero, D., Petrignet, J., Badia, A., ClosMV. Synthesis and pharmacological evaluation of huprine tacrineheterodimers: Subnanomolar dual binding site acetylcholinesteraseinhibitors (2005) J Med Chem, 48, pp. 1701-1714
• Camps, P., Formosa, X., Galdeano, C., Novel Donepezil basedinhibitors of acetyl- and butyryl cholinesterase and acetylcho-linesterase-induced -amyloid aggregation (2008) J Med Chem, 51, pp. 3588-3598
• Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., Decker, M., Design and synthesis of tacrine-ferulic acid hybrids as multi-potentanti-Alzheimer drug candidates (2008) Bioorg Med Chem Lett, 18, pp. 2905-2909
• Fernández-Bachiller, M.I., Pérez, C., Campillo, N.E., Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's dis-ease, with cholinergic, antioxidant, and neuroprotective properties (2009) Chem Med Chem, 4, pp. 828-841
• Fang, L., Appenroth, D., Decker, M., Synthesis and biologicalevaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates (2008) J Med Chem, 51, pp. 713-716
• Elsinghorst, P.W., Cieslik, J.S., Mohr, K., Tränkle, C., Gütschow, M., Firstgallamine-tacrine hybrid: Design, and characterization at cho-linesterases and the M2 muscarinic receptor (2007) J Med Chem, 50, pp. 5685-5695
• Muñoz-Ruiz, P., Rubio, L., García-Palomero, E., Design, synthe-sis, and biological evaluation of dual binding site acetylcho-linesterase inhibitors: New disease-modifying agents for Alz-heimer's disease (2005) J Med Chem, 48, pp. 7223-7233
• Bolognesi, M.L., Cavalli, A., Valgimigli, L., Multi-target-directeddrug design strategy: From a dual binding site acetylcholinesteraseinhibitor to a trifunctional compound against Alzheimer's disease (2007) J Med Chem, 50, pp. 6446-6449
• Harrison, S.M., Harper, A.J., Hawkins, J., BACE1 (β-secretase)transgenic and knockout mice: Identification of neurochemicaldeficits and behavioral changes (2003) Mol Cell Neurosci, 24, pp. 646-655
• McConlogue, L., Buttini, M., Anderson, J.P., Partial reduction ofBACE1 has dramatic effects on Alzheimer plaque and synaptic pa-thology in APP transgenic mice (2007) J Biol Chem, 282, pp. 26326-26334
• Hong, L., Koelsch, G., Lin, X., Structure of the protease domainof memapsin 2 (β-secretase) complexed with inhibitor (2000) Science G, 290, pp. 150-153
• Hong, L., Turner, R.T., Koelsch, G., Shin, D., Ghosh, A.K., Tang, J., Crystal structure of memapsin 2 (β-secretase) in complex with aninhibitor OM00-3 (2002) Biochemistry, 41, pp. 10963-10967
• Mancini, F., Naldi, M., Cavrini, V., Andrisano, V., Multiwell fluoromet-ric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors (2007) Anal Bioanal Chem, 388, pp. 1175-1183
• Fu, H., Li, W., Luo, J., Promising anti-Alzheimer's dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity (2008) Biochem Biophys Res Commun, 366, pp. 631-636
• Rosini, M., Andrisano, V., Bartolini, M., Melchiorre, C., Organic Com-pounds Useful For the Treatment of Alzheimer's Disease, their Useand Method of Preparation, , WO 2006/080043 A2
• Piazzi, L., Cavalli, A., Colizzi, F., Multi-target-directed coumarinderivatives: HAChE and BACE1 inhibitors as potential anti-Alzheimer compounds (2008) Bioorg Med Chem, 18, pp. 423-426
• Camps, P., Formosa, X., Galdeano, C., Pyrano [3,2-c]quinoline 6-chlorotacrine hybrids as a novel family of acetylcho-linesterase- and -amyloid-directed anti-Alzheimer compounds (2009) J Med Chem, 52, pp. 5365-5379
• Raves, M.L., Harel, M., Pang, Y.P., Silman, I., Kozikowski, A.P., Sussman, J.L., Structure of acetylcholinesterase complexed with the nootropicalkaloid, (-)-huperzine A (1997) Nature Struct Biol, 4, pp. 57-63
• Dvir, H., Jiang, H.L., Wong, D.M., X-ray structures of Torpedocalifornica acetylcholinesterase complexed with (+)-huperzine Aand (-)-huperzine-B: Structural evidence for an active site rear-rangement (2002) Biochemistry, 41, pp. 10810-10818
• Barril, X., Kalko, S.G., Orozco, M., Luque, F.J., Rational design ofreversible acetylcholinesterase inhibitors (2002) Mini Rev Med Chem, 2, pp. 27-36
• Harel, M., Schalk, I., Ehret-Sabatier, L., Quaternary ligandbinding to aromatic residues in the active-site gorge of acetylcho-linesterase (1993) Proc Nat Acad Sci USA, 90, pp. 9031-9035
• Camps, P., Muñoz-Torrero, D., Tacrine-Huperzine, A., Hybrids (hupri-nes): A new class of highly potent and selective acetylcho-linesterase inhibitors of interest for the treatment of Alzheimer dis-ease (2001) Mini Rev Med Chem, 1, pp. 163-174
• Camps, P., El Achab, R., Görbig, D.M., Synthesis, in vitro phar-macology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potentialinterest for the treatment of Alzheimer's disease (1999) J Med Chem, 42, pp. 3227-3242
• Barril, X., Orozco, M., Luque, F.J., Predicting relative binding freeenergies of tacrine-huperzine A hybrids as inhibitors of acetylcho-linesterase (1999) J Med Chem, 42, pp. 5110-5119
• Camps, P., El Achab, R., Morral, J., New tacrine-huperzine Ahybrids (huprines): Highly potent tight-binding acetylcho-linesterase inhibitors of interest for the treatment of Alzheimer'sdisease (2000) J Med Chem, 43, pp. 4657-4666
• Dvir, H., Wong, D.M., Harel, M., 3D structure of Torpedo cali-fornica acetylcholinesterase complexed with huprine X at 2.1 Åresolution: Kinetic and molecular dynamic correlates (2002) Biochemistry, 41, pp. 2970-2981
• Camps, P., Gómez, E., Muñoz-Torrero, D., Binding of 13-amidopurines to acetylcholinesterase: Exploring the ligand-inducedconformational change of the Gly117-Gly118 peptide bond in theoxyanion hole (2006) J Med Chem, 49, pp. 6833-6840
• Pilger, C., Bartolucci, C., Lamba, D., Tropsha, A., Fels, G., Accurateprediction of the bound conformation of galanthamine in the activesite of Torpedo californica acetylcholinesterase using moleculardocking (2001) J Mol Graphics Model, 19, pp. 288-296
• Bartolucci, C., Pilger, C., Fels, G., Lamba, D., Three-dimensionalstructure of a complex of galanthamine (Nivalin) with acetylcho-linesterase from Torpedo californica: Implications for the design ofnew anti-Alzheimer drugs (2001) Proteins: Struct Funct Bioinf, 42, pp. 182-191
• Greenblatt, H.M., Kryger, G., Lewis, T., Silman, I., Sussman, J.L., Struc-ture of acetylcholinesterase complexed with (-)-galanthamine at2.3 Å resolution (1999) FEBS Lett, 463, pp. 321-326
• Bourne, Y., Taylor, P., Radi, Z., Marchot, P., Structural insights intoligand interactions at the acetylcholinesterase peripheral anionicsite (2003) EMBO J, 22, pp. 1-12
• Cavalli, A., Bottegoni, G., Raco, C., de Vivo, M., Recanatini, M.A., Computational study of the binding of propidium to the peripheralanionic site of human acetylcholinesterase (2004) J Med Chem, 47, pp. 3991-3999
• Szegletes, T., Mallender, W.D., Rosenberry, T.L., Nonequilibriumanalysis alters the mechanistic interpretation of inhibition of acetyl-cholinesterase by peripheral site ligands (1998) Biochemistry, 37, pp. 4206-4216
• Harel, M., Sonoda, L.K., Silman, I., Sussman, J.L., Rosenberry, T.L., Crystal structure of thioflavin T bound to the peripheral site ofTorpedo californica acetylcholinesterase reveals how thioflavin Tacts as a sensitive fluorescent reporter of ligand binding to the acy-lation site (2008) J Am Chem Soc, 130, pp. 7856-7861
• Kryger, G., Silman, I., Sussman, J.L., Structure of acetylcholinesterasecomplexed with E2020 (Aricept): Implications for the design ofnew anti-Alzheimer drugs (1999) Structure, 7, pp. 297-307
• Rydberg, E.H., Brumshtein, B., Greenblatt, H.M., Complexes ofalkylene-linked tacrine dimers with Torpedo californica acetylcho-linesterase: Binding of bis(5)-tacrine produces a dramatic rear-rangement in the active-site gorge (2006) J Med Chem, 49, pp. 5491-5500
• Colletier, J.P., Sanson, B., Bachon, F., Conformational flexibilityin the peripheral site of Torpedo californica acetylcholinesteraserevealed by the complex structure with a bifunctional inhibitor (2006) J Am Chem Soc, 128, pp. 4526-4527
• Gemma, S., Gabellieri, E., Huleatt, P., Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites (2006) J Med Chem, 49, pp. 3421-3425
• Haviv, H., Wong, D.M., Greenblatt, H.M., Crystal packing mediates enantioselective ligand recognition at the peripheral site ofacetylcholinesterase (2005) J Am Chem Soc, 127, pp. 11029-11036
• Bourne, Y., Kolb, H.C., Radic, Z., Sharpless, K.B., Taylor, P., Marchot, P., Freeze-frame inhibitor captures acetylcholinesterase in a uniqueconformation (2004) Proc Natl Acad Sci USA, 101, pp. 1449-1454
• Senapati, S., Bui, J.M., McCammon, J.A., Induced fit in mouse acetyl-cholinesterase upon binding a femtomolar inhibitor: A moleculardynamics study (2005) J Med Chem, 48, pp. 8155-8162
• Wong, D.M., Greenblatt, H.M., Dvir, H., Acetylcholinesterasecomplexed with bivalent ligands related to huperzine A: Experi-mental evidence for species-dependent protein-ligand complemen-tarity (2003) J Am Chem Soc, 125, pp. 363-373
• Greenblatt, H.M., Guillou, C., Guénard, D., The complex of abivalent derivative of galanthamine with Torpedo acethylcho-linesterase displays drastic deformation of the active-site gorge:Implications for structure-based drug design (2004) J Am Chem Soc, 126, pp. 15405-15411
• Bartolucci, C., Haller, L.A., Jordis, U., Fels, G., Lamba, D., ProbingTorpedo californica acetylcholinesterase catalytic gorge with twonovel bis-functional galanthamine derivatives (2010) J Med Chem, 53, pp. 745-751
• Adcock, S.A., McCammon, J.A., Molecular dynamics: Survey ofmethods for simulating the activity of proteins (2006) Chem Rev, 106 (1589), p. 615
• Kua, J., Zhang, Y., McCammon, J.A., Studying enzyme binding speci-ficity in acetylcholinesterase using a combined molecular dynamicsand multiple docking approach (2002) J Am Chem Soc, 124, pp. 8260-8267
• Bartolucci, C., Perola, E., Cellai, L., Brufani, M., Lamba, D., Backdoor opening implied by the crystal structure of a carbamoylatedacetylcholinesterase (1999) Biochemistry, 38, pp. 5714-5719
• Rampa, A., Bisi, A., Valenti, P., Acetylcholinesterase inhibitors:Synthesis and structure-activity relationships of [N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]aminoalkoxyheteroaryl derivatives (1998) J Med Chem, 41, pp. 3976-3986
• Rampa, A., Piazzi, L., Belluti, F., Acetylcholinesterase inhibitors:SAR and kinetic studies on [N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]aminoalkoxyaryl derivatives (2001) J Med Chem, 44, pp. 3810-3820
• Belluti, F., Rampa, A., Piazzi, L., Cholinesterase inhibitors:Xanthostigmine derivatives blocking the acetylcholinesterase-induced -amyloid aggregation (2005) J Med Chem, 48, pp. 4444-4456
• Nachon, F., Nicolet, Y., Viguié, N., Engineering of a monomericand low-glycosylated form of human butyrylcholinesterase (2002) Eur J Biochem, 269, pp. 630-637
• Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J.C., Nachon, F., Crystal structure of human butyrylcholinesterase and of its com-plexes with substrate and products (2003) J Biol Chem, 278, pp. 41141-41147
• Ngamelue, M.N., Homma, K., Lockridge, O., Asojo, O.A., Crystallization and X-ray structure of full-length recombinant human butyryl-cholinesterase (2007) Acta Cryst, F63, pp. 723-727
• Radic, Z., Pickering, N.A., Vellom, D.C., Camp, S., Taylor, P., Threedistinct domains in the cholinesterase molecule confer selectivityfor acetyl- and butyrylcholinesterase inhibitors (1993) Biochemistry, 32, pp. 12074-12084
• Butini, S., Campiani, G., Borriello, M., Exploiting protein fluc-tuations at the active-site gorge of human cholinesterases: Futureoptimization of the design strategy to develop extremely potent in-hibitors (2008) J Med Chem, 51, pp. 3154-3170
• Elsinghorst, P.W., Cieslik, J.S., Mohr, K., Tränkle, C., Gütschow, M., Firstgallamine-tacrine hybrid: Design and characterization at cho-linesterases and the M2 muscarinic receptor (2007) J Med Chem, 50, pp. 5685-5695
• Tumiatti, V., Milelli, A., Minarini, A., Structure-activity relation-ships of acetylcholinesterase noncovalent inhibitors based on apolyamine backbone. 4. Further investigation on the inner spacer (2008) J Med Chem, 51, pp. 7308-7312
• Pan, L., Tan, J.H., Hou, J.Q., Huang, S.L., Gu, L.Q., Huang, Z.S., Design,synthesis and evaluation of isainditigotone derivates as acetylcho-linesterase and butyrylcholinesterase inhibitors (2008) Bioorg Med Chem Lett, 18, pp. 3790-3793
• Vassar, R., Bennett, B.D., Babu-Khan, S., Beta-secretase cleavageof Alzheimer's amyloid precursor protein by the transmembraneaspartic protease BACE (1999) Science, 286, pp. 735-741
• Yan, R., Bienkowski, M.J., Shuck, M.E., Membrane-anchoredaspartyl protease with Alzheimer's disease beta-secretase activity (1999) Nature, 402, pp. 533-537
• Sinha, S., Anderson, J.P., Barbour, R., Purification and cloning ofamyloid precursor protein beta-secretase from human brain (1999) Nature, 402, pp. 537-540
• Sinha, S., Lieberburg, I., Cellular mechanisms of beta-amyloid production and secretion (1999) Proc Natl Acad Sci USA, 9, pp. 11049-11053
• Ghosh, A.K., Bilcer, G., Harwood, C., Structure-based design:Potent inhibitors of human brain memapsin 2 (beta-secretase) (2001) J Med Chem, 44, pp. 2865-2868
• John, V., Beck, J.P., Bienkowski, M.J., Sinha, S., Heinrikson, R.L., Humanbeta-secretase (BACE) and BACE inhibitors (2003) J Med Chem, 46, pp. 4625-4630
• Hong, L., Koelsch, G., Lin, X., Structure of the protease domainof memapsin 2(beta-secretase) complexed with inhibitor (2000) Science, 290, pp. 150-153
• Ghosh, A.K., Shin, D., Downs, D., Design of potent inhibitors forhuman brain memapsin 2 (β-secretase) (2000) J Am Chem Soc, 122, pp. 3522-3523
• Hong, L., Tang, J., Flap position of free memapsin 2 (beta-secretase),a model for flap opening in aspartic protease catalysis (2004) Biochemistry, 43, pp. 4689-4695
• Patel, S., Vuillard, L., Cleasby, A., Murray, C.W., Yon, J., Apo andinhibitor complex structures of BACE (beta-secretase) (2004) J Mol Biol, 343, pp. 407-416
• Shimizu, H., Tosaki, A., Kaneko, K., Hisano, T., Sakurai, T., Nukina, N., Crystal structure of an active form of BACE1, an enzyme resposible for amyloid beta protein production (2008) Mol Cell Biol, 28, pp. 3663-3971
• Yu, N., Hayik, S.A., Wang, B., Liao, N., Reynolds, C.H., Merz Jr., K.M., Assigning the protonation states of the key aspartates in β-secretaseusing QM/MM X-ray structure refinement (2006) J Chem Theory Comput, 2, pp. 1057-1069
• Polgár, T., Keserü, G.M., Virtual screening for β-secretase (BACE1)inhibitors reveals the importance of protonation states at Asp32 andAsp228 (2005) J Med Chem, 48, pp. 3749-3755
• Park, H., Lee, S., Determination of the active site protonation state of-secretase from molecular dynamics simulation and docking experiment: Implications for structure-based inhibitor design (2003) J AmChem Soc, 125, pp. 16416-16422
• Rajamani, R., Reynolds, C.H., Modeling the protonation states of thecatalytic aspartates in β-secretase (2004) J Med Chem, 47, pp. 5159-5166
• Huang, D., Caflisch, A., Efficient evaluation of binding free energyusing continuum electrostatics solvation (2004) J Med Chem, 47, pp. 5791-5797
• Murray, C.W., Callaghan, O., Chessari, G., Application of frag-ment screening by X-ray crystallography to beta-secretase (2007) J Med Chem, 50, pp. 1116-1123
• Hanessian, S., Yun, H., Hou, Y., Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic andheterocyclic peptidomimetics (2005) J Med Chem, 48, pp. 5175-5190
• Stachel, S.J., Coburn, C.A., Steele, T.G., Conformationally biasedP3 amide replacvement of beta-secretase inhibitors (2006) Bioorg Med Chem Lett, 16, pp. 641-644
• Freslkos, J.N., Fobian, Y.M., Benson, T.E., Design of potentinhibitors of human beta-secretase. Part 2 (2007) Bioorg Med Chem Lett, 17, pp. 78-81
• Turner III, R.T., Hong, L., Koelsch, G., Ghosh, A.K., Tang, J., Structurallocations and functional roles of new subsites S5, S6, and S7 inmemapsin 2 (beta-secretase) (2005) Biochemistry, 44, pp. 105-112
• Hanessian, S., Yang, G., Rondeau, J.M., Neumann, U., Betschart C,Tintelnot-Blomley M. Structure-based design and synthesis of mac-roheterocyclic peptidomimetic inhibitors of the aspartic proteasebeta-site amyloid precursor protein cleaving enzyme (BACE) (2006) J Med Chem, 49, pp. 4544-4567
• Coburn, C.A., Stachel, S.J., Li, Y.M., Identification of a smallmolecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases (2004) J Med Chem, 47, pp. 6117-6119
• Stachel, S.J., Coburn, C.A., Steele, T.G., Structure-based design ofpotent and selective cell-permeable inhibitors of human beta-secretase (BACE-1) (2004) J Med Chem, 47, pp. 6447-6450
• Congreve, M., Aharony, D., Albert, J., Application of fragmentscreening by X-ray crystallography to the discovery of aminopyri-dines as inhibitors of beta-secretase (2007) J Med Chem, 50, pp. 1124-1132
• Edwards, P.D., Albert, J.S., Sylvester, M., Application of fragment-based lead generation to the discovery of novel, cyclicamidine beta-secretase inhibitors with nanomolar potency, cellularactivity, and high ligand efficiency (2007) J Med Chem, 50, pp. 5912-5925
• Cole, D.C., Manas, E.S., Stock, J.R., Acylguanidines as small-moleculae b-secretase inhibitors (2006) J Med Chem, 49, pp. 6158-6161
• Cole, D.C., Stock, J.R., Chopra, R., Acylguanidine inhibitors ofbeta-secretase: Optimization of the pyrrole ring substituents extend-ing into the S1 and S3 substrate binding pockets (2008) Bioorg MedChem Lett, 18, pp. 1063-1066
• Malamas, M.S., Erdei, J., Gunawan, I., Aminoimidazoles aspotent and selective human beta-secretase (BACE1) inhibitors (2009) J Med Chem, 52, pp. 6314-6323
• Malamas, M.S., Barnes, K., Johnson, M., Di-substituted pyridinylaminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors (2010) Bioorg Med Chem, 18, pp. 630-639
• Nowak, P., Cole, D.C., Aulabaugh, A., Discovery and initialoptimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors (2010) Bioorg Med Chem Lett, 20, pp. 632-635
• Godemann, R., Madden, J., Krämer, J., Fragment-based discov-ery of BACE1 inhibitors using functional analysis (2009) Biochemistry, 48, pp. 10743-10751
• Wang, Y.S., Strickland, C., Voigt, J.H., Application of fragment-based NMR screening, X-ray crystallography, structure-based de-sign, and focused chemical library design to identify novel μMleads for the development of nM BACE-1 (-site APP cleaving en-zyme 1) inhibitors (2010) J Med Chem, 53, pp. 942-950
• Zhu, Z., Sun, Z.Y., Ye, Y., Discovery of cyclic acylguanidines ashighly potent and selective -site amyloid cleaving enzyme(BACE) inhibitors: Part I - Inhibitor design and validation (2010) J MedChem, 53, pp. 951-965

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------